Close Menu

NEW YORK (360Dx) – Recent changes in physician behavior around monitoring patient response to therapeutic monoclonal antibodies (t-mAbs) is boosting demand for clinical testing of these drugs.

And this demand will likely continue to grow as new t-mAbs come to market and doctors continue to explore more customized dosing regimens, said Maria Willrich, an assistant professor of laboratory medicine and pathology and medicine at the Mayo Clinic.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.